Skip to main content

Table 3 Response to neoadjuvant chemotherapy and survival according to HER2 status

From: HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

 

HER2 1 + 

HER2 2 + 

p-value

N = 160

N = 77

 

Variable

n

%

N

n

%

N

 

Sataloff score

  

143

  

70

0.61

 TANA / TANB

23

16.1

 

14

20

  

 No pCR

120

83.9

 

56

80

  

RCB score

  

69

  

37

1

 0

10

14.5

 

5

13.5

  

 No pCR

59

85.5

 

32

86.5

  

RCB or Sataloff score

  

149

  

75

0.77

 pCR

24

16.1

 

14

18.7

  

 No pCR

125

83.9

 

61

81.3

  
  1. HER2 Human epidermal growth factor receptor 2, RCB Residual breast Cancer Burden, pCR Pathological complete response